Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906402 | 1.00 | CYP1A2 (0.55) | CYP1A2CES2CES1NPSR1NR1H4 | |
| SCHEMBL23353552 | 0.92 | AHR (0.54) | CYP1A2CES2CES1NPSR1NR1H4 | |
| SCHEMBL28225760 | 0.90 | CES2 (0.56) | CYP1A2CES2CES1NPSR1NR1H4 | |
| SCHEMBL12679 | 0.90 | — | — | |
| SCHEMBL28318341 | 0.90 | CES2 (0.62) | CES2CES1NR1H4PTGS2LMNA | |
| SCHEMBL6203955 | 0.90 | — | — | |
| Benzidine SCHEMBL28531320 | 0.87 | ACHE (0.62) | CYP1A2CES2CES1NPSR1NR1H4 | |
| Phosphine SCHEMBL22129260 | 0.87 | — | — | |
| Bromide SCHEMBL28687084 | 0.87 | CES2 (0.59) | CES2CES1NR1H4PTGS2LMNA | |
| Hydrochloric Acid SCHEMBL8996220 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166961-B1 | N- (HYDROPHOBE-SUBSTITUTED) VANCOSAMINYL [PSI[C(=NH) NH] TPG4] VANCOMYCIN AND [PSI[CH2NH]TPG4] VANCOMYCIN | SCRIPPS RESEARCH INST (US) | 2023-06-07 | — | — | EP | claimed |
| US-20200071359-A1 | PERIPHERAL MODIFICATIONS ON POCKET-REDESIGNED VANCOMYCIN ANALOGS SYNERGISTICALLY IMPROVE ANTIMICROBIAL POTENCY AND DURABILITY | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-05 | — | — | US | claimed |
| US-10577395-B2 | N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-03-03 | — | — | US | claimed |
| EP-3532483-A1 | PERIPHERAL MODIFICATIONS ON POCKET-REDESIGNED VANCOMYCIN ANALOGS SYNERGISTICALLY IMPROVE ANTIMICROBIAL POTENCY AND DURABILITY | The Scripps Research Institute (US) | 2019-09-04 | — | — | EP | claimed |
| WO-2018081797-A1 | PERIPHERAL MODIFICATIONS ON POCKET-REDESIGNED VANCOMYCIN ANALOGS SYNERGISTICALLY IMPROVE ANTIMICROBIAL POTENCY AND DURABILITY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-03 | — | — | WO | claimed |
| US-20170152291-A1 | N- (HYDROPHOBE-SUBSTITUTED) VANCOSAMINYL [PSI-[C(=NH) NH] TPG4] VANCOMYCIN AND [PSI-[CH2NH]TPG4] VANCOMYCIN | THE SCRIPPS RESEARCH INSTITUTE | 2017-06-01 | — | — | US | claimed |
| EP-3166961-A1 | N- (HYDROPHOBE-SUBSTITUTED) VANCOSAMINYL [PSI[C(=NH) NH] TPG4] VANCOMYCIN AND [PSI[CH2NH]TPG4] VANCOMYCIN | The Scripps Research Institute (US) | 2017-05-17 | — | — | EP | claimed |
| WO-2016007855-A1 | N- (HYDROPHOBE-SUBSTITUTED) VANCOSAMINYL [Ψ[C(=NH) NH] TPG4] VANCOMYCIN AND [Ψ[CH2NH]TPG4] VANCOMYCIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-01-14 | — | — | WO | claimed |
| EP-0979809-B1 | Process for the preparation of 4-chlorobiphenylenes | CLARIANT GMBH (DE) | 2003-01-29 | — | — | EP | claimed |
| US-6066766-A | Process for the preparation of 4-chlorobiphenyls | CLARIANT GMBH (DE) | 2000-05-23 | — | — | US | claimed |
| EP-0979809-A1 | Process for the preparation of 4-chlorobiphenylenes | Clariant GmbH (DE) | 2000-02-16 | — | — | EP | claimed |
| CN-117658785-A | Preparation method of olanzapine side chain and preparation method of olanzapine | 广东新达瑞生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4282861-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | Lapto Co., Ltd. (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-6156815-A | Acid-curable binder systems containing 1,2-disulfones | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-6066766-A | Process for the preparation of 4-chlorobiphenyls | CLARIANT GMBH (DE) | 2000-05-23 | — | — | US | disclosed |
| EP-0979809-A1 | Process for the preparation of 4-chlorobiphenylenes | Clariant GmbH (DE) | 2000-02-16 | — | — | EP | disclosed |
| US-5985950-A | Acid-curable binder systems containing 1,2 disulfones | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5717003-A | LATENT ACID CATALYST | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | AOC1, ODC1, PIEZO1 | CYP1A2 670/4885CES2 176/4885CES1 441/4885 |
| US-10577395-B2 | N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin | VNN1, VAC14, RPN1 | CYP1A2 4812/4885CES2 3994/4885CES1 4062/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | CYP1A2 3911/4885CES2 3547/4885CES1 2342/4885 |
| US-20200071359-A1 | PERIPHERAL MODIFICATIONS ON POCKET-REDESIGNED VANCOMYCIN ANALOGS SYNERGISTICALLY IMPROVE ANTIMICROBIAL POTENCY AND DURABILITY | DDOST, DNPEP, AAAS | CYP1A2 4721/4885CES2 1957/4885CES1 4297/4885 |
| US-20170152291-A1 | N- (HYDROPHOBE-SUBSTITUTED) VANCOSAMINYL [PSI-[C(=NH) NH] TPG4] VANCOMYCIN AND [PSI-[CH2NH]TPG4] VANCOMYCIN | VPS4B, HPN, VNN1 | CYP1A2 4694/4885CES2 1921/4885CES1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.